Therapeutic options for MASLD & MASH remain limited.
A new standardized rapid animal model reproduces key features of metabolic liver disease within ~8 weeks, supporting faster #preclinical development.
🎥 Watch the video: youtu.be/n-YC_Dpko2A
@frankuschner.bsky.social
#LiverSky #Hepatology
Acute decompensation of cirrhosis carries high 90-day mortality, but prediction remains challenging.
Adding signatures of large #extracellularvesicles may improve scores and prediction.
🎥 youtu.be/24-STOSjLeY
#EFCLIF @rautoupe.bsky.social @easlnews.bsky.social @europeliver.bsky.social
#LiverSky
In this video, we explore how emergency granulopoiesis, the rapid production of immune cells during crisis, becomes dysregulated in liver failure.
🎥 Watch here: youtu.be/ebN14TCLE24
#LiverSky #LiverFailure #LiverDisease #TranslationalResearch
📺New masterclass!
‘Data repositories & their access and publication rights’ covers the history of databases, an overview of repositories used in DECISION & provides a hands-on recipe on how to make the best out of different types of data
⏯️ youtu.be/aoA0WC1yaqs
#bioinformatics
DECISION's Year-in-Review2️⃣0️⃣2️⃣5️⃣
💙Networking session at EASL2025
🩵New publication on maladaptive emergency granulopoiesis
💙Met at Final General Assembly in Bologna
🩵Released 3 high-level lectures
We look forward to continuing our collaboration in 2026, finishing strong, and maximizing our impact 💪
New keynote out now!
🌟 Prof. Rubén Francés explains how LSECtin shapes immune tolerance and inflammation in advanced chronic liver disease.
Watch here: www.youtube.com/watch?v=pY9H...
#LiverSky #cirrhosis #inflammation
New DECISION study in @jhepatology.bsky.social: maladaptive emergency granulopoiesis predicts poor outcomes in acutely #decompensatedcirrhosis.
This could guide early identification and novel therapies.
www.sciencedirect.com/science/arti...
#ACLF #LiverSky #Hepatology @easlnews.bsky.social
That’s a wrap on our final DECISION GA!
From COMBAT & PROSPECT updates to forward-looking discussions and feedback, we’re proud of our shared achievements and motivated to keep advancing ACLF & decompensated cirrhosis research together.
#LiverSky
Our final GA is a look back and forward - from major scientific milestones to future discoveries!
After a keynote by Prof. Rubén Francés, partners shared results on omics integration, biomarkers & systems medicine - and closed today with a masterclass on data repositories. #cirrhosis
Next week: the final DECISION General Assembly in Madrid! 🎉
Celebrating 5+ years of science, collaboration, & results
@rautoupe.bsky.social @concentris.bsky.social
@navarrabiomed.bsky.social
@bioeticayderecho.bsky.social
@medblab.bsky.social
@europeliver.bsky.social
@easlnews.bsky.social et al
The latest DECISION Masterclass is live!
💡 Clinical Bioinformatics – It’s More Than Pressing a Button with Núria Planell, Cristina Sanchez & David Gomez-Cabrero.
Watch here: https://youtu.be/UBm1_JGhw6M
#Bioinformatics #ClinicalResearch #ACLF
Today is #WorldHepatitisDay! We spotlight two DECISION partners deeply committed to #liverhealth:
🔬 @easlnews.bsky.social – advancing #hepatology research
🧡 @europeliver.bsky.social – amplifying the voice of liver patients
Together, we work toward a healthier future beyond ACLF.
#Cirrhosis
🔥 We’ve hit 50% recruitment in the #COMBATtrial!
Huge thanks to all involved!💙
@rautoupe.bsky.social @hopitalbeaujon.bsky.social @hospitalclinic.bsky.social @rwth.bsky.social @uni-muenster.de @brunslab.bsky.social @medblab.bsky.social @frankuschner.bsky.social
#LiverSky #ClinicalTrial
🎥 New keynote online!
Prof. Richard Moreau, Director of #EFCLIF, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency.
Watch now 👉 https://youtu.be/KWoUbTsNjQM
#LiverSky #Hepatology
🎉 Exciting news: We’ve surpassed 500 followers on @linkedin.com!
Follow us there for updates on trials, science, and more 👉 www.linkedin.com/company/deci...
#ClinicalResearch #DECISIONproject
Consider joining this event by @a-tango.bsky.social and @crowdhelix.com!
"Industrial Perspective on Drug Development Challenges for Clinical Trials"
📅 4th June 2025
🕚 11:00 am CEST / 🕙 10:00 am BST
Register via this link: inevent.uk/en/Crowdheli...
It’s #ClinicalTrialsDay! At DECISION, we’re proud of our COMBAT & PROSPECT trials advancing care in decompensated cirrhosis.
💡COMBAT Q&A videos in multiple languages help engage patients ➡️ www.youtube.com/playlist?lis...
Thanks to all who make our trials possible! #LiverResearch
✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!
Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp
💡 Big moments:
#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)
#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin
#POSTER SAT-145-YI by Enrico Pompili (UNIBO) proposes a personalized management approach for patients with cirrhosis and ascites, based on real-world data from long-term albumin therapy. #EASL2025
🩺 Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis
#E_POSTER SAT-184-YI by Mimma Bonomo (UNITO) explores how coexisting diabetes mellitus affects prognosis in patients hospitalized with acute decompensation of cirrhosis.
#EASL2025
🦠The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course
#POSTER SAT-518 by @beccsipollsi.bsky.social from @rwth.bsky.social at #EASL2025
@brunslab.bsky.social
@easlnews.bsky.social
🧪 Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes
#POSTER SAT-122-YI by Alberto Calleri (UNITO) examines how acute kidney disease affects outcomes in patients with acutely decompensated cirrhosis.
📅 Presented at #EASLCongress | #EASL2025
@easlnews.bsky.social
❤️ Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population
#POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@inserm.fr, APHP, EF CLIF)
📅 Presented at the #EASLCongress | #EASL2025
@easlnews.bsky.social
Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk.
@rwth.bsky.social
@brunslab.bsky.social
@easlnews.bsky.social
#Cirrhosis #ACLF #EASL2025"
Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉
@navarrabiomed.bsky.social
@easlnews.bsky.social
#Epigenetics #LiverResearch
Javier Fernandez (FCRB) is giving the hepatologist perspective on management of MDR infections in cirrhosis as part of the EASL/ESCMID Symposium: MDR infections - a challenge in decompensated cirrhosis at #EASL2025
#LiverDisease #Cirrhosis #Hepatology @easlnews.bsky.social
Is the etiological work-up of #PSVD a one-size-fits-all?
DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease".
#EASLCongress #EASL2025 #LiverResearch
@easlnews.bsky.social
How do you build&lead a successful research team?
The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @rautoupe.bsky.social shared practical insights on building&maintaining a high-performing team.
@inserm.fr #EASL2025
DECISION consortium member Sophie Lotersztajn from the French research institute @inserm.fr at a late-afternoon abstract session today at #EASLCongress in Amsterdam, the Netherlands, about #fibrosis, #hepatocyte and #liver #regeneration. 🩺
#EASL2025 @easlnews.bsky.social
Congrats on presenting your poster in the Track Hub 4 this afternoon, @beccsipollsi.bsky.social ! 🙌
